SpringWorks Therapeutics Inc (SWTX) Stock: What Does the Chart Say Friday?

Overall market sentiment has been high on SpringWorks Therapeutics Inc (SWTX) stock lately. SWTX receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

SpringWorks Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on SWTX!

See Full SWTX Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With SWTX Stock Today?

SpringWorks Therapeutics Inc (SWTX) stock is down -0.03% while the S&P 500 has risen 0.4% as of 10:50 AM on Friday, Mar 8. SWTX is down -$0.01 from the previous closing price of $52.50 on volume of 282,910 shares. Over the past year the S&P 500 is higher by 29.71% while SWTX has risen 68.13%. SWTX lost -$4.89 per share in the over the last 12 months.

More About SpringWorks Therapeutics Inc

SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers. Click Here to get the full Stock Report for SpringWorks Therapeutics Inc stock.